Avience Biomedicals IPO: Key Facts on a Two-Year-Old SME
· 4 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.
Avience Biomedicals’ ₹30.24 crore NSE SME IPO: a 2-year-old diagnostics maker with tripling profit. Price band, financials and risks, set out.
Last Updated: June 2026
Avience Biomedicals Limited, a diagnostics and medical-device company, has launched a ₹30.24 crore IPO on the NSE SME platform.
Revenue has nearly doubled in a year. Profit has more than tripled.
The company is about two years old.
Let us break it down.
Understanding the Business
Avience Biomedicals Limited is a Noida-based manufacturer of in-vitro diagnostic (IVD) products and medical devices.
The company was incorporated in June 2024 and operates in the healthcare diagnostics ecosystem by manufacturing and supplying products used by hospitals, laboratories, diagnostic centres, and research institutions.
Its product portfolio includes:
· Rapid diagnostic test kits
· Viral transport media
· Serology reagents
· Biochemistry reagents
· Hematology analysers
· Oxygen concentrators
· Various diagnostic consumables and medical devices
Beyond manufacturing its own products, the company also distributes certain third-party medical equipment.
The business primarily operates in the B2B and B2G segments, supplying products to healthcare institutions rather than directly to retail consumers.
Avience is also planning a new manufacturing facility within the YEIDA Medical Device Park, which forms one of the major objectives of the IPO.
Financial Performance
Revenue Growth
The company reported:
· FY24 Revenue: ₹24.37 crore
· FY25 Revenue: ₹45.97 crore
This represents nearly 89% growth in one year.
Profitability
· FY24 Profit After Tax: ₹2.14 crore
· FY25 Profit After Tax: ₹7.23 crore
That means profit more than tripled within a year.
Return Ratios
The company has reported a Return on Net Worth (RoNW) in the high-40% range.
Limited Operating History
Avience Biomedicals has a short financial history.
The company was incorporated in June 2024, meaning investors currently have only about two years of audited financial information available.
That creates several challenges:
Growth Sustainability Is Unproven
A single year of growth does not establish a long-term trend. Many businesses experience temporary spikes due to:
· Large one-time contracts
· Industry-specific events
· Inventory cycles
· Unusual market conditions
With only two years of data, it becomes difficult to determine whether current growth rates can continue.
Limited Historical Benchmarking
Established businesses allow investors to study performance across different economic cycles. With Avience, that historical context simply does not exist yet.
Valuation Comparison Is Difficult
There is currently no closely comparable listed company of similar size and business structure. Without direct peers, valuation comparison is limited.
IPO Details at a Glance
Here are the key details of the issue:
This is a pure fresh issue.
Unlike IPOs that contain an Offer for Sale (OFS), none of the existing shareholders are selling shares to the public. Every rupee raised will go directly into the company.
| Item | Value | As of |
|---|---|---|
| Price band | ₹208 | 29 Jul 2026 |
| Lot size | 600 shares | 29 Jul 2026 |
| Issue size | ₹30.24 Cr | 29 Jul 2026 |
| Exchange | NSE SME | 29 Jul 2026 |
| Issue type | SME | 29 Jul 2026 |
| Opens | 18 Jun 2026 | 29 Jul 2026 |
| Closes | 22 Jun 2026 | 29 Jul 2026 |
| Allotment | 23 Jun 2026 | 29 Jul 2026 |
| Listing | 25 Jun 2026 | 29 Jul 2026 |
How Will the IPO Proceeds Be Used?
According to the offer documents, the company plans to utilise the IPO proceeds for:
New Manufacturing Facility
A portion of the funds will be used to establish a new manufacturing unit, helping expand production capacity.
Working Capital Requirements
Growing businesses often require additional funds to purchase inventory, manage receivables, and support day-to-day operations. Working capital remains a major focus area.
General Corporate Purposes
The remaining proceeds will be used for general corporate purposes.
The High Minimum Investment
One characteristic to note is the minimum application amount.
Because Avience is an SME IPO, the lot size is substantially larger than what investors typically see in mainboard IPOs.
Lot Size
· 600 shares per lot
· Retail minimum: 2 lots
· Total minimum application: 1,200 shares
At the upper price band of ₹208, the minimum investment works out to approximately ₹2.5 lakh.
That is dramatically higher than a typical mainboard IPO application, which often requires only ₹15,000–₹20,000.
Understanding SME Liquidity Risk
Liquidity is a risk in SME IPOs.
Liquidity simply refers to how easily investors can buy or sell shares.
Mainboard companies often have:
· Thousands of daily buyers and sellers
· Large trading volumes
· Narrow bid-ask spreads
SME-listed companies generally experience:
· Lower trading activity
· Fewer participants
· Wider price spreads
· More difficult exits
Entering a position may be easier than exiting one.
Liquidity risk is often as important as business risk in SME investing.
Key Risks
Short Track Record
The company's operating history remains limited.
Growth May Moderate
Growth rates may not be sustained.
SME Liquidity Constraints
Post-listing trading activity may be relatively low.
Customer and Supplier Concentration
Dependence on specific customers or suppliers can create operational risks.
Import Dependency
Reliance on imported components and materials can expose the business to currency fluctuations and supply-chain disruptions.
High Capital Commitment
The minimum investment size increases concentration risk for retail investors.
Summary
Figures and facts:
· Revenue rose from ₹24.37 crore in FY24 to ₹45.97 crore in FY25.
· Profit after tax rose from ₹2.14 crore to ₹7.23 crore.
· The IPO proceeds are intended for business expansion.
Risks:
· The operating history is short.
· Valuation benchmarking is difficult.
· SME liquidity risks apply.
· The minimum investment size is substantial.
Before forming any opinion, reading the Red Herring Prospectus (RHP), understanding the risk factors, and evaluating personal risk tolerance remain essential steps.
Disclaimer
This is written for educational and informational purposes only. Nothing here constitutes investment advice or a recommendation to buy or sell securities. All data is sourced from publicly available information. Investments in securities markets are subject to market risks — please read all offer documents carefully before investing.
